Market closed · data as of 27 Aug 2026 · source NSE via Alphave. Open the live chart →
Emcure Pharmaceuticals is a Pune-based pharma company with a strong domestic branded-generics franchise — notably in gynaecology, cardiology, blood-related therapies (it is known for its strength in women's health and injectables such as iron preparations) and HIV antiretrovirals — plus international sales across Europe, Canada and emerging markets. It manufactures a broad range of dosage forms including complex injectables and biologics, and listed via IPO in 2024. Founder Satish Mehta's family and Bain Capital have been key shareholders.
It is consistently ranked among the top players in Indian gynaecology therapy by prescriptions.
Emcure Pharmaceuticals Ltd. is a constituent of NIFTY 500, NIFTY SMALLCAP 250. See where it sits on the market heatmap →
Consolidated annual figures taken from Emcure Pharmaceuticals Ltd.'s own filed statements — not estimates, and not restated by us. The most recent period shown is FY26 (year ended 31 Mar 2026).
| Metric | FY26 | FY25 |
|---|---|---|
| EPS (basic, ₹) | 48.77 | 36.43 |
| Book value / share (₹) | 262.50 | 244.96 |
| Return on equity | 18.6% | 14.7% |
| Return on capital employed | 25.4% | 19.6% |
| Operating margin | 15.8% | 13.8% |
| Net margin | 10.2% | 9.0% |
| EBITDA | ₹1,865 Cr | ₹1,474 Cr |
| Free cash flow | ₹396 Cr | ₹445 Cr |
| Total debt | ₹1,204 Cr | ₹732 Cr |
| Debt to equity | 0.24 | 0.16 |
| Interest coverage | 10.1 | 6.2 |
| Current ratio | 1.46 | 1.74 |
| Shares outstanding | 18,95,90,000 | 18,94,83,000 |
Open the full income statement, balance sheet and cash flow for EMCURE →
As disclosed for the quarter ended 30 Jun 2026.
Institutional ownership changes quarter to quarter. See daily FII and DII flows across the market →
Companies Alphave classifies in the same sub-sector, closest by market capitalisation.